Editas Medicine's gene-edited therapy reni-cel has shown early clinical success, with some reports indicating it has been effective against severe sickle cell disease. However, the company is also facing challenges, including layoffs and difficulties in finding a partner for the therapy. The status of the program is uncertain, with some outlets reporting it has been shelved, while others suggest it continues to show promise.